Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis Reply
Journal Articles
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- July 1, 2009
has subject area
- 11 Medical and Health Sciences (FoR)
- 14 Economics (FoR)
- General & Internal Medicine (Science Metrix)